<p>PRKD1 is downregulated in non-small-cell lung cancer (NSCLC). Whether and how PRKD1 regulates tumorigenesis and metastasis is previously unknown. Here, we report that PRKD1 negatively regulates β-catenin protein abundance. PRKD1 promotes ubiquitination and degradation of EIF5A. EIF5A upregulates β-catenin and activates the Wnt signaling pathway. Thus, the PRKD1/EIF5A/β-catenin axis modulates the Wnt signaling pathway in NSCLC. Functionally, PRKD1 inhibits cell proliferation and metastasis both in vitro and in vivo. PRKD1 is downregulated and EIF5A is upregulated in NSCLC. Lower PRKD1 and higher EIF5A predict a worse patient survival. Our study suggests that the PRKD1/EIF5A/β-catenin axis is involved in the carcinogenesis of NSCLC and may serve as a new therapeutic target for NSCLC.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

PRKD1/EIF5A/β-catenin axis inhibits tumorigenesis and metastasis in non-small-cell lung cancer

  • Yu Wang,
  • Mengyu Zhang,
  • Lijun Fang,
  • Jiajia Qu,
  • Chen Huo,
  • Rui Li,
  • Jie Yao,
  • Yiqing Qu

摘要

PRKD1 is downregulated in non-small-cell lung cancer (NSCLC). Whether and how PRKD1 regulates tumorigenesis and metastasis is previously unknown. Here, we report that PRKD1 negatively regulates β-catenin protein abundance. PRKD1 promotes ubiquitination and degradation of EIF5A. EIF5A upregulates β-catenin and activates the Wnt signaling pathway. Thus, the PRKD1/EIF5A/β-catenin axis modulates the Wnt signaling pathway in NSCLC. Functionally, PRKD1 inhibits cell proliferation and metastasis both in vitro and in vivo. PRKD1 is downregulated and EIF5A is upregulated in NSCLC. Lower PRKD1 and higher EIF5A predict a worse patient survival. Our study suggests that the PRKD1/EIF5A/β-catenin axis is involved in the carcinogenesis of NSCLC and may serve as a new therapeutic target for NSCLC.